| OSRX® Bimatoprost + Brimonidine + Dorzolamide | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dosing | qam | ||||||||||
| Chem Specs | bimatoprost 0.01% , brimonidine 0.15%, , dorzolamide 2.0% | ||||||||||
| Quantities | 5ml, | ||||||||||
| Cost | 25.00 | ||||||||||
| Class | bimatoprost: Prostaglandin analog. brimonidine: Relatively selective alpha-2 agonist. dorzolamide : Carbonic anhydrase inhibitor | ||||||||||
| Usage | Single container preparation reduces cost and enhances compliance.
| Contraindications |
| bimatoprost Hypersensitivity to bimatoprost or other included ingredients. brimonidine
Neonates and infants (under the age of 2 years). Brimonidine hypersensitivity. dorzolamide Sulfonamide hypersensitivity.
Pediatric use |
Not recommended below the age of 16 due to potential increased pigmentation with chronic use.
|
Pregnancy |
There are no adequate studies in pregnant women for these ingredients. Teratogenicity shown in |
rabbits at 37x the human dose but not at 16x. Caution |
Bimatorost: lid, lash and iris pigmentation increases with chronic use. Iris pigentation remains |
after discontinuation.
| Compounded in OSRX 503A/503B approved pharmacy. BAK preserved.
|
|
